Share
March 04, 2021 Reinforcements arrive for the anticovid vaccine. An agreement has been signed between Novartis and Curevac for the production of the whey. Starting in the second quarter of 2021, 50 million doses will be produced until a production of 200 million doses is reached in 2022.
Preparation for the start of production, technology transfer and tests have already started. Production will take place in a new high-tech manufacturing facility that was already under construction at the Novartis Kundl site in Austria.
The first phase of the product will be delivered to Curevac for the subsequent production process and filling.